BAJAJ BROKING

Notification close image
No new Notification messages
card image
Seshaasai Technologies Ltd IPO
Apply for the Seshaasai Technologies Ltd IPO through UPI in Just minutes
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

How to Apply for the Corona Remedies Limited IPO: Step-by-Step Investment Guide

Corona Remedies Limited operates in the pharmaceutical formulations segment with a portfolio covering women’s healthcare, cardio-diabeto, pain management, urology, and several multispecialty categories. The company’s market presence is based on its distribution network across different regions in India and the manufacturing facilities located in Gujarat. Its portfolio includes a range of branded products used in multiple therapeutic areas, and the company engages with healthcare professionals through medical representatives. The company positions itself within the domestic branded formulations space and participates in selected therapeutic segments based on its product range and internal focus areas.

Investors can apply for the IPO through online platforms provided by registered intermediaries. The application process generally includes logging into the trading interface or bank application that offers the ASBA facility, selecting the IPO section, and choosing the relevant issue. The investor then enters bid details and confirms the application according to the available options. The funds remain blocked in the linked account until the allocation process is completed, as per the procedures followed by the intermediaries. The application steps may vary slightly depending on the intermediary interface, and applicants can refer to the official issue documents and disclosures for further procedural clarity.

For more details, visit the Corona Remedies Limited IPO page.

Corona Remedies Limited IPO Details and Objectives

Details

Information

IPO Date

December 8, 2025 to December 10, 2025

Issue Size

61,71,101 shares (aggregating up to ₹655.37 Cr)

Price Band

₹1008 to ₹1062 per share

Lot Size

14 shares

Listing At

BSE, NSE

Purpose of the IPO

  • Undertake the Offer for Sale of Equity Shares of face value of 10 each aggregating up to 6,553.71 million by the Selling Shareholders

  • Achieve the benefits of listing the Equity Shares on the Stock Exchanges

Timeline of Corona Remedies Limited IPO

Event

Date

IPO Open Date

Mon, Dec 8, 2025

IPO Close Date

Wed, Dec 10, 2025

Tentative Allotment

Thu, Dec 11, 2025

Initiation of Refunds

Fri, Dec 12, 2025

Credit of Shares to Demat

Fri, Dec 12, 2025

Tentative Listing Date

Mon, Dec 15, 2025

Cut-off time for UPI mandate confirmation

5 PM on Wed, Dec 10, 2025

Pricing & Lot Size of Corona Remedies Limited IPO

Price Band for the IPO

  •  ₹1008 to ₹1062 per share

Minimum Lot Size and Application Details

Application

Lots

Shares

Amount

Retail (Min)

1

14

₹14,868

Retail (Max)

13

182

₹1,93,284

S-HNI (Min)

14

196

₹2,08,152

S-HNI (Max)

67

938

₹9,96,156

B-HNI (Min)

68

952

₹10,11,024

Corona Remedies Limited IPO Application Process

The Corona Remedies Limited IPO application process can be completed online through your trading platform. Below is a step-by-step guide to applying for the IPO:

Step 1: Login to Your Trading Platform

Access your trading account using the broker's app or website.

Step 2: Navigate to the IPO Section

Go to the IPO section to view active IPO listings.

Step 3: Select the Open IPO and Click Apply

Locate Corona Remedies Limited IPO in the list of available IPOs and click the ‘Apply’ button.

Step 4: Enter the Quantity of Shares You Wish to Apply For

Specify the number of shares (lot size: 14 shares) within the price band of ₹1008 to ₹1062 per share.

Step 5: Provide Your UPI ID

Enter your UPI ID for payment authorisation and ensure sufficient funds in your bank account.

Step 6: Confirm the Application

Review your application details and confirm the UPI mandate before 5 PM on the last application day.

Step 7: Complete the Process and Wait for Allotment

Submit the application and monitor the allotment status to check if shares have been allocated to you.

Financial Health and Performance

Key Financial Metrics

  • Total Assets: Grew from ₹595.02 crore in FY23 to ₹1,012.38 crore as of June 2025.

  • Total income: Reached ₹348.56 crore in FY25.

  • Profit After Tax (PAT): Stood at ₹46.20 crore for June 2025.

  • Net Worth: Recorded at ₹607.02 crore in FY25.

  • Reserves and surplus: Stood at ₹545.86 crore in FY25.

  • EBITDA: Stood at ₹71.80 crore in June 2025.

Recent Performance and Growth Prospects

  • Based on available financial disclosures, the company reported an increase in its asset base over the recent period, reflecting higher recorded holdings in its balance sheet.

  • Reported income for the period indicated growth in operational activity, supported by revenue from its product portfolio in various therapeutic segments.

  • Profit after tax filings showed a positive outcome during the stated period, indicating earnings generated from ongoing operations after accounting for expenses and taxes.

  • Net worth reported for the period reflected an improvement in shareholder equity, supported by internal financial reserves.

  • Disclosed reserves and surplus data indicated accumulation of retained earnings over time, contributing to overall financial strength.

  • The reported operating earnings data suggested the presence of earnings generated from core activities before accounting for interest, taxes, depreciation, and amortisation.

  • The recorded movement in financial indicators may be viewed as part of the company’s ongoing performance trend, based on filings available in public domain sources.

Investment Risks and Opportunities

Potential Risks of Investing in the IPO

  • The company operates in a segment where product approvals, regulatory requirements, and compliance updates can influence business activities and timelines.

  • Demand patterns in therapeutic areas may vary due to changing prescription trends, healthcare access levels, and competition within the broader domestic market landscape.

Opportunities and Growth Potential

  • The company’s focus on multiple therapeutic categories offers access to a wider patient base through its portfolio and regional coverage.

  • Expansion of branded formulations in selected therapeutic areas, supported by marketing networks and manufacturing facilities, may provide scope for continued market participation.

Key Performance Indicator (KPI)

KPI

Values

ROE

27.50%

ROCE

41.32%

Debt/Equity

0.10

RoNW

24.65%

PAT Margin

12.49%

EBITDA Margin

20.55%

Price to Book Value

10.71

Market Capitalisation

₹6,495.20 Cr.

Corona Remedies Limited IPO Registrar & Lead Managers

Registrar

Lead Manager(s)

Bigshare Services Pvt.Ltd.

JM Financial Ltd. 

Company Address of Corona Remedies Limited

Corona Remedies Ltd.

CORONA House, C – Mondeal Business Park

Near Gurudwara S. G. Highway

Thaltej

Ahmedabad, Gujarat, 380059

Phone: +91 79 4023 3000

Email: complianceofficer@coronaremedies.com

Website: https://www.coronaremedies.com/

Conclusion

Corona Remedies Limited operates within the pharmaceutical formulations space and participates in selected therapeutic segments through its portfolio and distribution network. The company’s activities cover multiple treatment areas, supported by manufacturing facilities and engagement with healthcare professionals. The details related to the IPO, including timelines and offer structure, are available through the official documents published for the issue.

The application process can be completed through platforms that provide access to IPO bidding facilities, and applicants may review the information made available by authorised intermediaries. Investors can follow the stated procedure while ensuring that all steps are completed within the timelines indicated in the issue schedule. The details mentioned reflect disclosures available in the public domain and may be reviewed through exchange filings and offer documents for clarity.

Interested in more opportunities? Check out our Upcoming IPO section for new listings and don’t forget to check your Corona Remedies IPO allotment status.  

Frequently Asked Questions

No result found

search icon

Read More Blogs

Disclaimer :

The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes. The securities are quoted as an example and not as a recommendation. Past performance is not necessarily a guide to future performance.

The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.

Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.

BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.

Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

[ Read More ]

For more disclaimer, check here : https://www.bajajbroking.in/disclaimer

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

11 lakh+ Users

icon-with-text

4.8 App Rating

icon-with-text

4 Languages

icon-with-text

₹7,600+ Cr MTF Book

icon-with-text
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|